Overview
Gilead Sciences, headquartered in Foster City, California, researches, develops and commercialises medicines in HIV and AIDS, liver diseases, haematology, oncology, inflammation and respiratory diseases.[2] Its antiviral brands include Genvoya, Descovy, Odefsey, Truvada, Epclusa and Harvoni.[2] Forbes records sales of US$29.8bn, up 3.8%, and profit of US$9.2bn, a margin of about 31%, the fourth highest in this ranking.[2] With 17,000 employees, it generates around US$1.75m of sales per employee, one of the highest ratios among the top 25. Forbes notes the company was founded by Michael L. Riordan on 22 June 1987.[2] Gilead remains in sixteenth position. Its reliance on HIV medicines gives it steady revenue but limited diversification compared with the larger groups.
Gilead Sciences strengths and limitations
Strengths
- Profit margin of about 31%
- High sales per employee
- Leading HIV franchise
Limitations
- Concentrated in antivirals
- Sales growth of 3.8%
- Oncology business smaller than peers'
Appears in
Gilead Sciences peers and competitors
Companies ranked in the same lists as Gilead Sciences.
Johnson & Johnson- Amgen
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Takeda Pharmaceutical
GSK plc
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.